Table 1

Patient characteristics

G-NECAC
(n=173) (%)
P values
RAM (n=17) (%)Without RAM (n=13) (%)
Age
 Median (range)74 (53–85)64 (57–73)67 (24–84)0.03
Gender
 Male17 (100)7 (54)110 (64)<0.01
ECOG PS
 014 (82)11 (85)109 (63)0.1
 12 (12)2 (15)55 (32)
 21 (6)0 (0)9 (5)
Ki-67
 Median (n, range)75%(15, 50–95%)80% (11, 20%–95%)
 Missing (n)(2)(2)
Previous gastrectomy
 Yes5 (29)4 (31)39 (23)0.67
Number of previous treatment
 113 (76)12 (92)117 (68)0.13
 ≥24 (24)1 (8)56 (32)0.13
Target lesion
 Yes17 (100)13 (100)135 (78)0.02
Site of metastases
 Liver11 (65)9 (70)58 (34)<0.01
 Lymph nodes11 (65)13 (100)99 (57)<0.01
 Lung1 (6)0 (0)15 (9)0.51
 Peritoneum0 (0)0 (0)86 (50)<0.01
Number of metastases
 1–217 (100)11 (85)150 (87)0.33
 ≥30 (0)2 (15)23 (13)
ChemotherapyRAM+paclitaxel 13 (76)Amrubicin 6 (46)RAM+ paclitaxel 126 (73)0.76
RAM+irinotecan 2 (12)Irinotecan 4 (31)RAM+ irinotecan 25 (14)
Rmonotherapy 2 (12)Paclitaxel 3 (23)RAMmonotherapy 22 (13)
  • AC, adenocarcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; G-NEC , gastric neuroendocrine carcinoma; RAM, ramucirumab.